Actively Recruiting
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
Led by PERROD Guillaume · Updated on 2025-09-03
272
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lynch syndrome (LS) is the most common genetic predisposition syndrome for colorectal cancer (CRC), responsible for around 2-4% of cancers. It is characterized by a pathogenic germline mutation in one of the DNA mismatch repair genes (path\_MMR) MLH1, MSH2, MSH6, PMS2 or a deletion in the 3' region of the Epcam gene. Patients followed up for LS are at high risk of developing CRC at an early age, and have a high cumulative CRC risk. In this context, CRC screening by colonoscopy is of major importance, as it is associated with a reduction in both CRC incidence and mortality. In France, the Institut National du Cancer (INCa) recommends colonoscopy with indigo carmine chromoendoscopy (CE), as it is associated with a significant increase in the adenoma detection rate (ADR) compared with white light. However, EC is not routinely performed in clinical practice, as it is a time-consuming technique requiring a dedicated slot with a trained operator. Recent years have seen the emergence of artificial intelligence techniques for real-time polyp detection aids or CADe devices. These easy-to-use systems have shown very promising results compared with high-definition (HD) white light. Indeed, data from the first meta-analysis of 5 randomized controlled trials (4354 patients) confirmed a significantly higher ADD in the CADe group than in the HD group (36.6% vs. 25.2%; 95% CI\], 1.27-1.62; P \< 0.01; I2 Z 42%) 10. The CAD EYE system (Fujifilm) is a CADe device supporting both detection (sensitivity \> 95%) and characterization of colonic polyps in real time. To date, artificial intelligence has never been evaluated for CRC screening in patients followed up for LS. The aim of this work is to evaluate the effectiveness of the CAD EYE system in this specific population. To this end, we intend to conduct a randomized, controlled, non-inferiority trial comparing CAD EYE with CE in patients with LS.
CONDITIONS
Official Title
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed pathogenic mutation in one of the Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, or EpCAM)
- Male or female of legal age at time of colonoscopy prescription
- Patient agrees to participate in the study
- Person affiliated with or benefiting from a social security scheme
- Free, informed, and express consent provided
You will not qualify if you...
- Patient has undergone total colectomy with ileoanal or ileosigmoid anastomosis
- History of Crohn's disease or ulcerative colitis
- Known allergy or intolerance to polyethylene glycol and ascorbic acid
- Unable to undergo fractionated colonic preparation
- Inadequate colonic preparation with Boston sub-score less than 2 per segment
- Patient is under guardianship or a protected person
- Patient does not understand French or cannot read
- Person not affiliated to a social security system
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Européen Georges-Pompidou HEGP
Paris, France, 75015
Actively Recruiting
Research Team
G
Guillaume Perrod, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here